Share on StockTwits

NuVasive (NASDAQ:NUVA) COO Keith Valentine unloaded 2,500 shares of NuVasive stock on the open market in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $35.14, for a total value of $87,850.00. Following the transaction, the chief operating officer now directly owns 77,285 shares of the company’s stock, valued at approximately $2,715,795. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at Jefferies Group reiterated a “buy” rating on shares of NuVasive in a research note on Wednesday, July 30th. They now have a $48.00 price target on the stock, up previously from $45.00. Separately, analysts at Barclays reiterated an “equal weight” rating on shares of NuVasive in a research note on Wednesday, July 30th. They now have a $42.00 price target on the stock, up previously from $40.00. Finally, analysts at Goldman Sachs upgraded shares of NuVasive from a “neutral” rating to a “buy” rating in a research note on Wednesday, June 25th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. NuVasive presently has an average rating of “Buy” and a consensus target price of $42.60.

NuVasive (NASDAQ:NUVA) traded up 1.02% during mid-day trading on Wednesday, hitting $35.51. 248,068 shares of the company’s stock traded hands. NuVasive has a 52-week low of $23.17 and a 52-week high of $39.89. The stock has a 50-day moving average of $35.40 and a 200-day moving average of $35.32. The company’s market cap is $1.667 billion.

NuVasive (NASDAQ:NUVA) last released its earnings data on Tuesday, July 29th. The company reported $0.28 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.25 by $0.03. The company had revenue of $190.70 million for the quarter, compared to the consensus estimate of $177.50 million. During the same quarter in the prior year, the company posted $0.20 earnings per share. The company’s quarterly revenue was up 15.1% on a year-over-year basis. Analysts expect that NuVasive will post $1.12 EPS for the current fiscal year.

NuVasive, Inc is a medical device company, that focuses on developing minimally disruptive surgical products and procedures for the spine.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.